AU2017326347B2 - Compositions with permeation enhancers for drug delivery - Google Patents

Compositions with permeation enhancers for drug delivery Download PDF

Info

Publication number
AU2017326347B2
AU2017326347B2 AU2017326347A AU2017326347A AU2017326347B2 AU 2017326347 B2 AU2017326347 B2 AU 2017326347B2 AU 2017326347 A AU2017326347 A AU 2017326347A AU 2017326347 A AU2017326347 A AU 2017326347A AU 2017326347 B2 AU2017326347 B2 AU 2017326347B2
Authority
AU
Australia
Prior art keywords
composition
certain embodiments
permeation enhancer
agent
sol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017326347A
Other languages
English (en)
Other versions
AU2017326347A1 (en
Inventor
Daniel S. Kohane
Rong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of AU2017326347A1 publication Critical patent/AU2017326347A1/en
Application granted granted Critical
Publication of AU2017326347B2 publication Critical patent/AU2017326347B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
AU2017326347A 2016-09-14 2017-09-14 Compositions with permeation enhancers for drug delivery Active AU2017326347B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394716P 2016-09-14 2016-09-14
US62/394,716 2016-09-14
PCT/US2017/051577 WO2018053140A1 (en) 2016-09-14 2017-09-14 Compositions with permeation enhancers for drug delivery

Publications (2)

Publication Number Publication Date
AU2017326347A1 AU2017326347A1 (en) 2019-03-21
AU2017326347B2 true AU2017326347B2 (en) 2023-07-20

Family

ID=61619716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017326347A Active AU2017326347B2 (en) 2016-09-14 2017-09-14 Compositions with permeation enhancers for drug delivery

Country Status (8)

Country Link
US (1) US20200138710A1 (https=)
EP (1) EP3512501A4 (https=)
JP (1) JP7277360B2 (https=)
KR (1) KR20190053215A (https=)
CN (2) CN109937033A (https=)
AU (1) AU2017326347B2 (https=)
CA (1) CA3036696A1 (https=)
WO (1) WO2018053140A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180128A (es) 2015-08-05 2018-04-24 Childrens Medical Center Composiciones con potenciadores de permeación para suministro de fármacos
CA3188400A1 (en) * 2020-08-03 2022-02-10 Daniel S. Kohane Thermo-sensitive permeation enhancing formulations for drug delivery
GB202100945D0 (en) * 2021-01-25 2021-03-10 Brightcure Ltd A composition useful for treating bacterial infections
DE202021106639U1 (de) 2021-10-08 2023-01-10 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mit beschränkter Haftung Neue Therapiekonzepte für die Behandlung von Otitis
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
CN118518439B (zh) * 2023-02-17 2025-09-16 清华大学 离子液体制剂和组织处理方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141949A1 (en) * 2000-11-22 2004-07-22 Rosenthal Gary J. Treatment of mucositis
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2017024282A1 (en) * 2015-08-05 2017-02-09 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0725628B1 (en) * 1994-08-30 2001-11-07 Alcon Laboratories, Inc. Thermally-gelling drug delivery vehicles containing cellulose ethers
WO2000007603A2 (en) * 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141949A1 (en) * 2000-11-22 2004-07-22 Rosenthal Gary J. Treatment of mucositis
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8822410B2 (en) * 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2017024282A1 (en) * 2015-08-05 2017-02-09 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. L. HUNTER, C. JAGANNATH, A. TINKLEY, C. A. BEHLING, F. NOLTE: "Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 39, no. 2, 1 February 1995 (1995-02-01), US , pages 435 - 439, XP055475869, ISSN: 0066-4804, DOI: 10.1128/AAC.39.2.435 *

Also Published As

Publication number Publication date
JP2019533644A (ja) 2019-11-21
AU2017326347A1 (en) 2019-03-21
US20200138710A1 (en) 2020-05-07
CA3036696A1 (en) 2018-03-22
EP3512501A1 (en) 2019-07-24
WO2018053140A1 (en) 2018-03-22
KR20190053215A (ko) 2019-05-17
EP3512501A4 (en) 2020-04-29
CN109937033A (zh) 2019-06-25
CN120392650A (zh) 2025-08-01
JP7277360B2 (ja) 2023-05-18

Similar Documents

Publication Publication Date Title
US12053527B2 (en) Compositions with permeation enhancers for drug delivery
AU2017326347B2 (en) Compositions with permeation enhancers for drug delivery
JP7033789B2 (ja) トリグリセリド耳用製剤とその使用
RU2675360C2 (ru) Способы лечения местных микробных инфекций
KR102282183B1 (ko) 염증, 자가면역 장애 및 통증의 치료 방법
US20110166060A1 (en) Tympanic membrane permeating ear drops and uses thereof
US20190365906A1 (en) Random copolymer therapeutic agent carriers and assemblies thereof
JP2024170397A (ja) 薬物送達のための相乗的な透過促進剤を伴う組成物
CA3188400A1 (en) Thermo-sensitive permeation enhancing formulations for drug delivery
WO2025212563A1 (en) Injectable hydrogel based on liposome self-assembly for sustained release of small hydrophilic molecules
HK40006438A (en) Triglyceride otic formulations and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)